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Host-directed therapies for improving poor treatment outcomes
associated with the middle east respiratory syndrome coronavirus
infections
S U M M A R Y
Three years after its ﬁrst discovery in Jeddah Saudi Arabia, the novel zoonotic pathogen of humans, the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) continues to be a major threat to global health security.1 Sporadic community acquired cases of MERS continue to be reported from the
Middle East. The recent nosocomial outbreaks in hospitals in Seoul, Korea and at the National Guard Hospital in Riyadh, Saudi Arabia indicate the epidemic
potential of MERS-CoV. Currently there are no effective anti-MERS-CoV anti-viral agents or therapeutics and MERS is associated with a high mortality rate
(40%) in hospitalised patients. A large proportion of MERS patients who die have a range of pulmonary pathology ranging from pneumonia to adult
respiratory distress syndrome with multi-organ failure, compounded by co-morbidities, reﬂecting a precarious balance of interactions between the host-
immune system and MERS-CoV. Whilst we wait for new MERS-CoV speciﬁc drugs, therapeutics and vaccines to be developed, there is a need to advance a
range of Host-Directed Therapies. A range of HDTs are available, including commonly used drugs with good safety proﬁles, which could augment host
innate and adaptive immune mechanisms to MERS-CoV, modulate excessive inﬂammation and reduce lung tissue destruction. We discuss the rationale
and potential of using Host-Directed Therapies for improving the poor treatment outcomes associated with MERS. Carefully designed randomized
controlled trials will be needed to determine whether HDTs could beneﬁt patients with MERS. The recurrent outbreaks of MERS-CoV infections at
hospitals in the Middle East present unique opportunities to conduct randomized clinical trials. The time has come for a more coordinated global response
to MERS and a multidisciplinary global MERS-CoV response group is required to take forward priority research agendas.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The past two decades has seen the emergence and spread of novel
viral respiratory tract pathogens of humans, such as severe acute
respiratory syndrome coronavirus (SARS-CoV), H7N9 avian strain of
inﬂuenza A virus, swine inﬂuenza A H1N1, and Middle East
respiratory syndrome coronavirus (MERS-CoV), for which no speciﬁc
treatment options are available and carry a high morbidity and
mortality rate.1–5 MERS-CoV was ﬁrst reported from Jeddah in
September 2012 when it was isolated from a Saudi patient who died
of a severe respiratory illness and multi-organ failure.6 Since then
community and hospital acquired MERS cases have been reported
from twenty-nine countries from the Middle East, Africa, Europe,
North America and Asia.7 Three years since it’s ﬁrst discovery, many
fundamental questions regarding the epidemiology, pathogenesis,
immune responses and optimal treatment regimens of MERS-CoV
remain unanswered.8–10MERS-CoV continues to be of global concern
as illustrated by recent nosocomial outbreaks at the National Guard
Hospital in Riyadh, Saudi Arabia11–13 and at hospitals in Seoul,
Republic of Korea.14–16 The Korean outbreak which resulted in
186 conﬁrmed MERS cases with 35 deaths arose from a Korean
traveler who imported MERS-CoV from the Middle East.17 As of
21 August 2015, there have been 1432 laboratory conﬁrmed cases of
human infection with 507 deaths (40% mortality).18http://dx.doi.org/10.1016/j.ijid.2015.09.005
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).2. Current deﬁciencies of MERS-CoV treatment
Current clinical management of seriously ill MERS patients is
fraught with difﬁculties.19,20 There are no MERS-CoV-speciﬁc anti-
viral, other therapeutic or immune based treatments approved for
treating patients. Thus supportive care is the main stay of
treatment and is focused on prevention of complications,
particularly organ failure, ARDS, and secondary bacterial infec-
tions.21 Due to the high mortality in hospitalized MERS cases,
empiric treatment has been tried on an ad hoc patient basis.
Reports of the empiric individual or combination use of steroids,
interferons (IFN-a and IFN–b), other generic anti-viral drugs have
been tried have been used to treat MERS patients with no
signiﬁcant effects on clinical outcome.22–28 There have been no
controlled randomized clinical trials of any treatment intervention
performed to date. The use of convalescence plasma, monoclonal
antibodies and mycophenolic acid are further options available
and require evaluation in controlled clinical trials. There are
several anti-MERS-CoV drugs in development but to date no anti-
MERS-CoV therapeutics have been developed or approved by
regulatory authorities. The unacceptable high mortality rate
associated with MERS-CoV and its epidemic potential, indicates
an urgent need for development of newer anti-MERS-CoV drugs,
vaccines and alternate treatment approaches.29,30ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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Infection with MERS-CoV presents as a spectrum of clinical
manifestations from asymptomatic, mild to severe disease which
progresses to multi-organ failure and death. A large proportion of
patients infected with MERS-CoV are either asymptomatic or have
mild illness and complete recovery occurs due to effective innate
and acquired immune responses which eradicates the infection.31
No comprehensive immunopathogenesis studies have been
conducted to date. The protective and deleterious human response
to MERS-CoV remains to be determined. Pneumonia and multi-
organ involvement is a common feature in patients with MERS.32
The high mortality seen in MERS-CoV could be attributed to acute
lung injury, development of acute respiratory distress syndrome
(ARDS).33 ARDS is associated with leaky alveolar-capillary inter-
faces with pulmonary oedema, hypoxia, polymorphonuclear
leucocytic or lymphocytic cells with upregulation of pro-inﬂam-
matory cytokines and gamma interferon and an aberrant immune
response, which results in further tissue damage and deterioration
of lung function. Sixty percent of MERS patients with acute lung
injury or ARDS either recover after receiving intensive care and 40%
of MERS patients succumb to the disease.34
A large majority of patients who die due to infection with MERS-
CoV may have some form of immunosuppression due to old age or
having co-morbid conditions (diabetes, chronic lung, renal, cardiac
or liver disease or have an underlying immunosuppressive
condition).35 It appears that the outcome of MERS patients may
represent a precarious balance of both host- and MERS-CoV-induced
immune signaling events.36 It is not known whether mortality is a
reﬂection of an ineffective host response to MERS-CoV or whether an
aberrant host immune response contributes to pathogenesis and
poor prognosis. Interventions that could manipulate this host-
pathogen relationship via modulation of the host response to MERS-
CoV infection may help improve mortality rates in patients with
MERS.37 For instance, genome analysis suggest that immune
signaling modulation may affect outcome,38 and adenosine deami-
nase may prevent MERS-CoV entry into host cells.39 A range of Host-
Directed Therapies (HDTs) have the potential for improving the
treatment outcomes of severe lung infections.40
4. Host-directed therapies for MERS
The general principles of using HDTs are to augment anti-
MERS-CoV protective immune mechanisms, modulate destructive
immune-mediated inﬂammatory responses, and protect tissues
from inﬂammatory damage. A range of HDT interventions are
available41,42 which require evaluation for treatment of patients
with MERS:
1) ‘Repurposed’ commonly used drugs with excellent safety
proﬁles include those being used for lowering cholesterol,
diabetes, arthritis, antibiotics, epilepsy and cancer, which can
modulate autophagy, promote other immune effector mecha-
nisms, antimicrobial peptide production and repair of damaged
tissues,
2) Micronutrient products with immune-modulatory effects,
3) Cellular therapy using mesenchymal stromal cells obtained
from patient’s own bone marrow to reduce aberrant inﬂamma-
tion, regenerating tissues and inducing anti-MERS-CoV immune
responses.
4.1. Repurposed drugs
Several commonly available products with a longstanding
safety record which are readily available and require evaluation astreatments for severe MERS, and for which open label clinical trials
should be considered.43 Statins have shown potential for treatment
of inﬂuenza44 and other diseases with lung injury.45 They induce
autophagy and maturation of phagosome and have anti-inﬂam-
matory effects through peroxisome proliferator-activated recep-
tor-g and transforming growth factor-b. Non-steroidal anti-
inﬂammatory drugs such as Indomethacin, Ibuprofen and Acet-
ylsalicylic acid inhibit cyclooxygenase and reduce inﬂammation
and tissue pathology;46 overt inﬂammatory immune responses,
have been curbed using etoposide in patients with severe inﬂuenza
infection,47 which may in part be due to differential susceptibility
of Treg (regulatoary T-cells).48 The diabetes drug Metformin
increases mitochondrial ROS production and enhances macro-
phage autophagy.49 Several cancer drugs such as Gleevac
(Imatinib)-a tyrosine kinase inhibitor, activate autophagy and
reduce inﬂammatory responses.50 Doxycycline has potential for
protection against destruction and degradation of tissue collagen
and other structural proteins through its matrix metallo proteinase
(MMP) inhibitor effect.51 A recent study describes a library of
290 compounds screened for antiviral activity against MERS-CoV
and severe acute respiratory syndrome coronavirus (SARS-CoV). Of
these 27 compounds with activity against both MERS-CoV and
SARS-CoV were identiﬁed.52 These compounds include inhibitors
of dopamine receptor used as anti-psychotic drugs and inhibitors
of estrogen receptors used for cancer treatment.
4.2. Autologous bone-marrow derived stromal cells
Mesenchymal stromal cells (MSCs) derived from the patient’s
own bone marrow may have the potential to modulate aberrant
immune responses through their anti-inﬂammatory and tissue-
repairing effects for severe viral and bacterial infections of the
lung.58,59 The use of adjunct therapy using MSCs derived from the
patient’s own bone marrow and expanded ex vivo before re-
infusion, is currently under evaluation for range of infectious and
non-communicable diseases and should be evaluated for improv-
ing treatment outcome of MERS-CoV in hospitalized cases, with
very encouraging and life-saving results in the MSCs treatment of
patients with ARDS.53
5. Advancing host-directed therapies for MERS
Repurposed drugs have well-deﬁned safety and pharmacokinetic
proﬁles their individual evaluations through controlled clinical trials
are required to deﬁne their effectiveness in treatment of severe cases
of MERS and patients with co-morbidities. Treatment outcome
measures would be effect on mortality, lung function, and long term
sequelae, immune responses, and resolution of lung inﬂammation
and tissue regeneration. To achieve optimal treatment several
variables need to be explored when trialing these agents including
patient’s age, the presence of co-morbid illness, the extent of disease
and the timing of the intervention. Carefully designed randomized
controlled trials will be needed to determine whether HDTs could
beneﬁt patients with MERS, and optimally these studies. HDT trials in
MERS could beneﬁt from experience in managing life-threatening
clinical situations, where overt inﬂammation caused by a ‘cytokine
storm’ in the context of T-cell based therapies of malignant diseases,
can be controlled. Highly activated T-cells are not responsive to
glucocortocosteriods,54–56 and yet may respond to newer drugs, such
as anti-TNF reagents (e.g. eternacept), anti-IL-6 and anti-IL-1beta.57
Many fundamental questions regarding MERS epidemiology,
pathogenesis, protective immune responses, viral kinetics, and
optimal treatment remain unanswered three years into its ﬁrst
discovery. A MERS-CoV response group is required and the
recurrent outbreaks of MERS-CoV infections at hospitals present
unique challenges for control of MERS-CoV and at the same time
Editorial / International Journal of Infectious Diseases 40 (2015) 71–74 73provides an opportunity to conduct randomized clinical trials and
answer priority research questions. The time has come for a more
coordinated global response to take forward important priority
epidemiological, translational clinical and basic science research
forward. The establishment of clinical trials capability within a
global consortia will develop infrastructure and build local
capacity to take forward further evaluations of new drugs,
therapeutics and vaccines
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